Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Katharina A MayerKlemens BuddePhilip F HalloranKonstantin DobererLionel RostaingFarsad EskandaryAnna ChristamentlMarkus WahrmannHeinz RegeleSabine SchranzSarah ElyChrista FirbasChristian SchörgenhoferAlexander KainzAlexandre LoupyStefan HärtleRainer BoxhammerBernd JilmaGeorg A BöhmigPublished in: Trials (2022)
gov NCT05021484 . Registered on 25 August 2021.
Keyphrases